Eli Lilly and Co at JPMorgan Healthcare Conference (Virtual) Transcript
Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside chat with Dave Ricks, Chairman and CEO of Eli Lilly. Dave, welcome, and great speaking with you today.
Good to be here.
Questions & Answers
Yes. Last year, we had the big donanemab update, and I think we're hot off the presses on some CMS decision, which we won't spend too much time on today, given the great amount of time to digest that. But would love to just hear some opening remarks just as you think about Lilly's positioning heading into 2022. The company's obviously incredibly well positioned. It's been a big outperformer versus peers. And I would just love to hear how you're thinking about the business as we start the new year.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
